Targets › PLK1
3 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 2; Oncology; next expected readout Nov 2026.
Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. Polo-like kinase proteins act by binding and phosphorylating…. (UniProt, P53350)
Open in Phaseline: the race on PLK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cardiff Oncology | Onvansertib Serine/threonine-protein kinase PLK1 inhibitor | PLK1 | Phase 2 | Metastatic Colorectal Cancer; Small-cell Lung Cancer; Breast Cancer; Pancreatic Cancer | Nov 2026 |
| SillaJen | BAL0891 Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) | TTK, PLK1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Nationwide Children's Hospital | PTC596 Polo-like kinase 1 (PLK1) inhibitor | PLK1 | Phase 1 | High Grade Glioma | Mar 2029 |
Metastatic Colorectal Cancer (1) Small-cell Lung Cancer (1) Breast Cancer (1) Pancreatic Cancer (1) Advanced Solid Tumor (1) High Grade Glioma (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.